Transcranial magnetic stimulation (TMS) for major depression: A multisite, naturalistic, observational study of quality of life outcome measures in clinical practice

CNS Spectrums

Volumn 18, Issue 6, 2013, Pages 322-332

  Janicak, Philip G ^a   Dunner, David L ^b,c   Aaronson, Scott T ^d   Carpenter, Linda L ^e   Boyadjis, Terrence A ^f   Brock, David G ^g   Cook, Ian A ^h   Lanocha, Karl ⁱ   Solvason, Hugh B ^j   Bonneh Barkay, Dafna ^g   Demitrack, Mark A ^g  

^a RUSH UNIVERSITY   (United States)

^b Center for Anxiety and Depression   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d SHEPPARD PRATT HEALTH SYSTEM   (United States)

^e BROWN UNIVERSITY   (United States)

^f Private Practice Plymouth Meeting   (United States)

^g Neuronetics   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ TMS Center of New England   (United States)

^j STANFORD UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

Clinical trial; depression; functional status; quality of life; transcranial magnetic stimulation

Indexed keywords

ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; EUROQOL 5 DIMENSION QUESTIONNAIRE; FEMALE; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NATURALISTIC INQUIRY; OBSERVATIONAL STUDY; PATIENT HEALTH QUESTIONNAIRE 9; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SELF REPORT; SHORT FORM 36; TRANSCRANIAL MAGNETIC STIMULATION; UNITED STATES; VERY ELDERLY;

EID: 84890029909     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852913000357     Document Type: Article

References (57)

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997; 349: 1498-1504.
2. Murray C, Lopez AD. Evidence-based health policy - lessons from the Global Burden of Disease Study. Science. 1996; 274(5288): 740-743.
3. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry. 2003; 64: 1465-1475.
4. Sackeim HA. The definition and meaning of treatmentresistant depression. J Clin Psychiatry. 2001; 62: 10-17.
5. Rush AJ, Thase ME, Dubé S. Research issues in the study of difficult-to-treat depression. Biol Psychiatry. 2003; 53: 743-753.
6. Janicak PG, Marder S, Pavuluri M. Principles and Practice of Psychopharmacotherapy, 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2011: 256-263.
7. Fava M, Rush AJ, Trivedi M, et al. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am. 2003; 26: 457-494.
8. Rush AJ, Fava M, Wisniewski SR, et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials. 2004; 25: 119-142.
9. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D implications for clinical practice. Am J Psychiatry. 2006; 163: 28-40.
10. Rush AJ, TrivediMH,Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006; 354: 1231-1242.
11. Fava M, Rush AJ, Wisniewski SR, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: A STAR*D report. Am J Psychiatry. 2006; 163: 1161-1172.
12. McGrath PJ, Stewart JW, Fava M, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry. 2006; 163: 1531-1541.
13. Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T3 augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry. 2006; 163: 1519-1530.
14. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006; 163: 1905-1917.
15. Janicak P, O'Reardon JP, Sampson SM, et al. Transcranial magnetic stimulation in the treatment of major depressive disorder: a comprehensive summary of safety experience from acute exposure, extended exposure, and during reintroduction treatment. J Clin Psychiatry. 2008; 69: 222-232.
16. Janicak PG, Nahas Z, Lisanby SH, et al. Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study. Brain Stimul. 2010; 3: 187-199.
17. George MS, Lisanby SH, Avery D, et al. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry. 2010; 67: 507-516.
18. Avery DH, Isenberg KE, Sampson SM, et al. Transcranial magnetic stimulation in the acute treatment of major depressive disorder: clincical response in an open-label extension trial. J Clin Psychiatry. 2008; 69: 441-451.
19. O'Reardon JP, Solvason HB, Janicak PG, et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry. 2007; 62: 1208-1216.
20. Demitrack MA, Thase M. Clinical significance of transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant depression: synthesis of recent data. Psychopharmacol Bull. 2009; 42: 5-38.
21. Carpenter LL, Janicak PG, Aaronson ST, et al. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depress Anxiety. 2012; 29(7): 587-596.
22. Connolly KR, Helmer A, Cristancho MA, et al. Effectiveness of transcranial magnetic stimulation in clinical practice post-FDA approval in the United States: results observed with the first 100 consecutive cases of depression at an academic medical center. J Clin Psychiatry. 2012; 73(4): e567-e573.
23. Shafi MM, Westover MB, Fox MD, et al. Exploration and modulation of brain network interactions with noninvasive brain stimulation in combination with neuroimaging. Eur J Neurosci. 2012; 35(6): 805-825.
24. Pascual-Leone A, Tormos JM, Keenan J, et al. Study and modulation of human cortical excitability with transcranial magnetic stimulation. J Clin Neurophysiol. 1998; 15: 333-343.
25. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients - results from the medical outcomes study. JAMA. 1989; 262: 914-919.
26. Broadhead WE, Blazer DG, George LK, et al. Depression, disability days, and days lost from work in a prospective epidemiologic survey. JAMA. 1990; 264: 2524-2528.
27. Kennedy N, Foy K, Sherazi R, et al. Long-term social functioning after depression treated by psychiatrists: a review. Bipolar Disord. 2007; 9: 25-37.
28. Fairclough DL. Design and Analysis of Quality of Life Studies in Clinical Trials. Boca Raton, FL: Chapman and Hall/CRC; 2002.
29. Fayers PM. Quality of Life: Assessment, Analysis and Interpretation. West Sussex, UK: Wiley; 2002.
30. Judd LL, Akiskal HS, Zeller PJ, et al. Psychosocial disability during the long-term course of unipolar major depressive disorder. Arch Gen Psychiatry. 2000; 57: 375-380.
31. Trivedi MH, Rush AJ, Wisniewski SR, et al. Factors associated with health-related quality of life among outpatients with major depressive disorder: a STAR*D report. J Clin Psychiatry. 2006; 67(2): 185-195.
32. Wisniewski SR, Rush AJ, Bryan C, et al. Comparison of quality of life measures in a depressed population. J Nerv Ment Dis. 2007; 195(3): 219-225.
33. McCall WV, Rosenquist PB, Kimball J, et al. Healthrelated quality of life in a clinical trial of ECT followed by continuation pharmacotherapy: effects immediately after ECT and at 24 weeks. J ECT. 2011; 27: 97-102.
34. Solomon DA, Leon AC, Coryell W, et al. Predicting recovery from episodes of major depression. J Affect Disord. 2008; 107: 285-291.
35. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992; 30: 473-483.
36. Brooks R. EuroQol: the current state of play. Health Policy. 1996; 37: 53-72.
37. Mann R, Gilbody S, Richards D. Putting the "Q" in depression QALYs: a comparison of utility measurement using EQ-5D and SF-6D health related quality of life measures. Soc Psychiatry Psychiatr Epidemiol. 2009; 44(7): 569-578.
38. Ware JE Jr, Kosinski M, Gandek B. SF-36 Health Survey: Manual and Interpretation Guide. Lincoln, RI: QualityMetric Incorporated, 1993, 2000.
39. www.euroqol.org.
40. http://www.ahrq.gov/rice/EQ5Dscore.htm#weights.
41. Macran S, Kind P. "Death" and the valuation of healthrelated quality of life. Medical Care. 2001; 39(3): 217-227.
42. Katzelnick DJ, Duffy FF, Chung H, et al. Depression outcomes in psychiatric clinical practice: using a selfrated measure of depression severity. Psychiatr Serv. 2011; 62(8): 929-935.
43. Cui Z, Faries DE, Gelwicks S, Novick D, Liu X. Early discontinuation and suboptimal dosing of duloxetine treatment in patients with major depressive disorder: analysis from a US third-party payer perspective. J Med Econ. 2012; 15: 134-144.
44. Hardeveld F, Spijker J, De Graaf R, Nolen WA, Beekman AT. Prevalence and predictors of recurrence of major depressive disorder in the adult population. Acta Psychiatr Scand. 2010; 122: 184-191.
45. Ware JE Jr, Kosinski M. SF-36 Physical & Mental Health Summary Scales: A Manual for Users of Version 1, 2nd ed. Lincoln, RI: QualityMetric Incorporated; 2001.
46. Dunner DL, Rush AJ, Russell JM, et al. Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. J Clin Psychiatry. 2006; 67: 688-695.
47. Gunther OH, Roick C, Angermeyer MC, et al. The responsiveness of EQ-5D utility scores in patients with depression: a comparison with instruments measuring quality of life, psychopathology and social functioning. J Affect Disord. 2007; 105: 81-91.
48. Sobocki P, Ekman M, Agren H, et al. Health-related quality of life measured with EQ-5D in patients treated for depression in primary care. Value Health. 2007; 10: 153-160.
49. Simon GE, Revicki DA, Grothaus L, et al. SF-36 summary scores: are physical and mental health truly distinct? Med Care. 1998; 36: 567-572.
50. Garcia-Cebrian A, Bauer M, Montejo AL, et al. Factors influencing depression endpoints research (FINDER): study design and population characteristics. Eur Psychiatry. 2008; 23: 57-65.
51. Walker V, Streiner DL, Novosel S, et al. Health-related quality of life in patients with major depression who are treated with moclobemide. J Clin Psychopharmacol. 1995; 15: 60S-67S.
52. Reed C, Monz BU, Perahia DG, et al. Quality of life outcomes among patients with depression after 6 months of starting treatment: results from FINDER. J Affect Disord. 2009; 113: 296-302.
53. Kroenke K, West SL, Swindle R, et al. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care. JAMA. 2001; 286: 2947-2955.
54. Yatham LN, Lecrubier Y, Fieve RR, et al. Quality of life in patients with bipolar I depression: data from 920 patients. Bipolar Disord. 2004; 6(5): 379-385.
55. ten Doesschate MC, Koeter MWJ, Bockting CLH, et al. Health related quality of life in recurrent depression: a comparison with a general population sample. J Affect Disord. 2010; 120(1-3): 126-132.
56. Sapin C, Fantino B, Nowicki ML, Kind P. Usefulness of EQ-5D in assessing health status in primary care patients with major depressive disorder. Health Qual Life Outcomes. 2004; 2: 20.
57. Peveler R, Kendrick T, Buxton M, et al. A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine. Health Technol Assess. 2005; 9(16): 1-134.